Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an update.
OncoSil Medical Ltd has updated details of its proposed non-renounceable pro rata issue of securities, lodging an amended Appendix 3B with the ASX. The company has revised the timetable for the offer, pushing back a key date from 12 March 2025 to 17 March 2025, and has also corrected the offer price of the retail offer options from $0.68 per security to $0.00, effectively indicating that the options will be issued at no subscription price. These changes clarify the commercial terms and timing of the capital raising structure, which may affect investor expectations and the attractiveness of participation in the retail component of the offer.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$0.80 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is an ASX-listed medical company that develops and commercialises oncology devices and therapies, with a focus on cancer treatment technologies. The company targets the healthcare and medical markets, seeking to provide innovative solutions for cancer care through its specialised products.
Average Trading Volume: 24,813
Technical Sentiment Signal: Sell
Current Market Cap: A$15.11M
See more data about OSL stock on TipRanks’ Stock Analysis page.